Breaking News Instant updates and real-time market news.

MNST

Monster Beverage

$42.01

0.57 (1.38%)

, GKOS

Glaukos

$45.79

0.29 (0.64%)

17:55
03/01/17
03/01
17:55
03/01/17
17:55

On The Fly: After Hours Movers

UP AFTER EARNINGS: Monster Beverage (MNST), up 11.9%... Glaukos (GKOS), up 8.3%... Casella Waste (CWST), up 6.9%... Health Insurance Innovations (HIIQ), up 4%... Pacific Ethanol (PEIX), up 4.1%... Broadcom (AVGO), up 3.9%. ALSO HIGHER: Aurinia Pharmaceuticals (AUPH), up 40.4% after it said that its Voclosporin study met its 48-week remission endpoints... Vermillion (VRML), up 17% after its ASPiRA LABs subsidiary announced a major contracted agreement with Blue Cross Blue Shield. DOWN AFTER EARNINGS: Pure Storage (PSTG), down 6.6%... Retrophin (RTRX), down 5.4%... Planet Fitness (PLNT), down 4.8%... Shake Shack (SHAK), down 4.4%... Nektar (NKTR), down 2.6%... Synergy Pharmaceuticals (SGYP), down 2.5%... Box (BOX), down 1.4%... Hudson Technologies (HDSN), down 1.2%. ALSO LOWER: AXT, Inc. (AXTI), down 9.3% after it filed to sell common stock... Juno Therapeutics (JUNO), down 7% after it said it was discontinuing development of JCAR015... Kratos Defense (KTOS), down 4.7% after it announced a common stock offering.

MNST

Monster Beverage

$42.01

0.57 (1.38%)

GKOS

Glaukos

$45.79

0.29 (0.64%)

CWST

Casella Waste

$12.11

0.43 (3.68%)

HIIQ

Health Insurance Innovations

$17.85

-0.1 (-0.56%)

PEIX

Pacific Ethanol

$8.35

0.5 (6.37%)

AVGO

Broadcom

$215.14

4.21 (2.00%)

AUPH

Aurinia Pharmaceuticals

$3.71

0.15 (4.21%)

VRML

Vermillion

$2.35

0.04 (1.73%)

PSTG

Pure Storage

$11.33

-0.07 (-0.61%)

RTRX

Retrophin

$21.50

0.23 (1.08%)

PLNT

Planet Fitness

$21.85

0.34 (1.58%)

SHAK

Shake Shack

$36.12

0.29 (0.81%)

NKTR

Nektar

$13.01

-0.07 (-0.54%)

SGYP

Synergy Pharmaceuticals

$5.68

-0.11 (-1.90%)

BOX

Box

$18.26

0.64 (3.63%)

HDSN

Hudson Technologies

$7.39

0.23 (3.21%)

AXTI

AXT, Inc.

$7.50

0.4 (5.63%)

JUNO

Juno Therapeutics

$25.31

1.27 (5.28%)

KTOS

Kratos Defense

$8.03

-0.22 (-2.67%)

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 02

    Mar

  • 02

    Mar

  • 02

    Mar

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 29

    Mar

  • 30

    Mar

  • 01

    Apr

MNST Monster Beverage
$42.01

0.57 (1.38%)

01/13/17
STFL
01/13/17
NO CHANGE
STFL
Monster Beverage Q4 revenue trends 'positive,' says Stifel
Stifel analyst Mark Astrachan says that the Q4 revenue trends preannounced by Monster were "positive." He says that the trends are "approximately inline with consensus estimates" but "meaningfully better than buy-side expectations." Astrachan keeps a $59 price target and a Buy rating on the shares.
01/13/17
BMOC
01/13/17
NO CHANGE
BMOC
Investor worries on Monster Beverage U.S,. sales misplaced, says BMO Capital
After Monster Beverage preannoucned its Q4 sales trends, BMO Capital analyst Amit Sharma says that investors' concerns regarding "sales growth deceleration in the U.S. appear misplaced." The analyst is now more confident about the company's results going forward and keeps a $55 price target and an Outperform rating on the shares.
01/13/17
JEFF
01/13/17
NO CHANGE
Target $58
JEFF
Buy
Jefferies sees Monster share rally after 'upbeat' analyst day
Jefferies analyst Kevin Grundy believes the "strong" commentary on Q4 and "bullish" long-term outlook from Monster Beverage's analyst day should drive a relief rally in the shares. The company is not seeing the slowdown implied by recent Nielsen results, Grundy tells investors in a research note. He found the analyst day "upbeat" and keeps the stock as a top pick with a Buy rating and $58 price target.
01/12/17
WELS
01/12/17
NO CHANGE
WELS
Market Perform
Wells sees negative risk/reward into Monster's investor meeting
Monster Beverage's risk/reward into today's investor meeting is negative, Wells Fargo analyst Bonnie Herzog told investors last night in a research note. She said her outlook for the company "continues to deteriorate" due to soft category trends, Java production issues, the "poor" rollout of Mutant and retailers' "modest" outlook for Monster in 2017. She expects "weak" Q4 results from the company and continues to have "more questions than answers." Herzog lowered her price target range for the shares to $44-$46 from $49-$51 and keeps a Market Perform rating on the name. Monster Beverage is down 83c to $43.16 in morning trading.
GKOS Glaukos
$45.79

0.29 (0.64%)

02/22/17
BMOC
02/22/17
INITIATION
BMOC
Outperform
Glaukos initiated with an Outperform at BMO Capital
BMO Capital analyst Joanne Wuensch started coverage of Glaukos with a $54 price target and an Outperform rating. She says that Glaukos is "the market leader in revolutionizing Micro-Invasive Glaucoma Surgery," and she adds that the glaucoma market is expected to grow to $7B in 2021. The analyst adds that reimbursement trends for the company's surgery are improving, while its gross margins are in the 80s percentage range.
01/06/17
STFL
01/06/17
UPGRADE
STFL
Buy
Glaukos upgraded to Buy from Hold at Stifel
01/06/17
STFL
01/06/17
UPGRADE
Target $45
STFL
Buy
Glaukos upgraded to Buy on favorable 2017 setup at Stifel
Stifel analyst Jonathan Block upgraded Glaukos to Buy from Hold saying favorable reimbursement should drive higher iStent selling prices and drive upside to 2017 revenue estimates. The analyst believes Alcon's competing product CyPass has "slightly stumbled" with its reimbursement coding initiative, which should moderate its near-term market share gains. Block upped his price target for Glaukos shares to $45 from $42.
02/09/17
PIPR
02/09/17
NO CHANGE
Target $50
PIPR
Overweight
Glaukos price target raised to $50 from $42 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Glaukos to $50 after hosting an investor call with a high volume cataract surgeon. The doctor confirmed a price increase for the iStent and implied that competition is more market expanding instead of direct, O'Brien tells investors in a research note. He continues to recommend investors own Glaukos.
CWST Casella Waste
$12.11

0.43 (3.68%)

05/09/16
STFL
05/09/16
UPGRADE
STFL
Buy
Casella Waste upgraded to Buy from Hold at Stifel
12/09/16
FANA
12/09/16
DOWNGRADE
Target $15
FANA
Equal-Weight
Casella Waste downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Corey Greendale downgraded Casella Waste to Equal-Weight citing valuation with the stock up 121% year-to-date. The analyst raised his price target for the shares to $15 from $14.
05/09/16
STFL
05/09/16
UPGRADE
STFL
Buy
Casella Waste upgraded on business model change at Stifel
As noted earlier, Stifel upgraded Casella to Buy from Hold. The firm believes that "a fundamental change" in the company's business model is increasing its free cash flow and lowering its leverage. Target $8.50.
06/27/16
STFL
06/27/16
NO CHANGE
STFL
Solid Waste sector upgraded to Overweight from Market Weight at Stifel
Stifel expects solid waste companies' Q2 results to show that their fundamentals were "very strong" as they benefited from good prices and strong volume growth. Stifel expects the sector to benefit from the search for defensive names in the wake of Brexit. It recommends that all investors own a solid waste stock. Companies in the sector include Waste Management (WM), Republic Services (RSG), Waste Connections (WCN), and Casella Waste (CWST)
HIIQ Health Insurance Innovations
$17.85

-0.1 (-0.56%)

09/15/16
LSCM
09/15/16
INITIATION
Target $9
LSCM
Buy
Health Insurance Innovations initiated with a Buy at Lake Street
Lake Street analyst Mark Argento started Health Insurance Innovations with a Buy rating and $9 price target.
06/09/16
RAJA
06/09/16
DOWNGRADE
RAJA
Market Perform
Health Insurance Innovations downgraded to Market Perform at Raymond James
Raymond James downgraded Health Insurance Innovations to Market Perform from Strong Buy. Analyst Steven Schwartz said the surprised proposal by the Department of Health and Human Services to change its definition of short term medical insurance could severely restrict the use and creates regulatory uncertainty.
06/07/16
NORL
06/07/16
INITIATION
Target $11
NORL
Outperform
Health Insurance Innovations initiated with an Outperform at Northland
Target $11.
12/30/16
LSCM
12/30/16
NO CHANGE
Target $20
LSCM
Buy
Health Insurance Innovations target raised to $20 from $13 at Lake Street
Lake Street analyst Mark Argento raised his price target for Health Insurance Innovations to $20 saying the company is continuing to see strong demand. The latest Affordable Care Act open enrollment period, which ended December 19, likely drove additional business to the company as "individuals got sticker shock and looked for cost effective insurance alternatives," Argento tells investors in a research note. He points out that Health Insurance Innovations raised its FY16 guidance four times over the year. The analyst keeps a Buy rating on the shares.
PEIX Pacific Ethanol
$8.35

0.5 (6.37%)

12/12/16
CHLM
12/12/16
NO CHANGE
Target $14
CHLM
Buy
Pacific Ethanol price target raised to $14 from $10 at Craig-Hallum
Craig-Hallum analyst Eric Stine said Pacific Ethanol's debt refinancing removes an overhang and provides a meaningful catalyst for the stock. The analyst, who views the refinancing as having been done at favorable terms, raised his price target on the stock to $14 from $10 and keeps a Buy rating on the shares.
08/15/16
CHLM
08/15/16
NO CHANGE
CHLM
Corn fundamentals positive for Pacific Ethanol, says Craig-Hallum
Craig-Hallum analyst Eric Stine says that corn prices will probably remain low, as crops look poised to set records. The analyst says that the ratio between corn prices and ethanol prices has remained at the highest levels since 1H15, despite recent declines in ethanol prices. He thinks that Pacific Ethanol's risk/reward ratio is positive and keeps a $9 price target and Buy rating on the shares.
05/24/16
RODM
05/24/16
INITIATION
Target $11
RODM
Buy
Pacific Ethanol initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Amit Dayal started Pacific Ethanol with a Buy rating and $11 price target. The company is employing multiple initiatives improve efficiencies and yields, and its cost structure should allow for margin expansion, the analyst contends.
AVGO Broadcom
$215.14

4.21 (2.00%)

02/27/17
RBCM
02/27/17
NO CHANGE
RBCM
Broadcom results, guidance should beat expectations, says RBC Capital
RBC Capital analyst Amit Daryanani says that Broadcom's January quarter results and its April quarter guidance should beat expectations. The analyst expects the company's wireless communications business to be more stable than investors expect, driven by strong iPhone sales, and he thinks that the growth of the company's wired business will be in the mid single percentage digits in fiscal 2017, coming in above Street expectations. The analyst keeps a $230 price target and a Top Pick rating on the stock.
02/27/17
KEYB
02/27/17
NO CHANGE
KEYB
Broadcom should be bought ahead of Q1 results, says KeyBanc
KeyBanc expects Broadcom to report in-line Q1 revenue and slightly higher than expected EPS. The firm thinks that 2H17 iPhone content gains, along with the company's new Purley products and multiple expansion, can push the stock higher. He recommends buying the shares ahead of the Q1 results.
02/27/17
LOOP
02/27/17
NO CHANGE
Target $244
LOOP
Buy
Broadcom price target raised to $244 from $211 at Loop Capital
Loop Capital analyst Betsy Van Hees raised her price target for Broadcom to $244 ahead of the company's Q1 results on Wednesday, March 1. Strength in Enterprise Storage should drive another beat and raise quarter, Van Hees tells investors in a pre-earnings research note. She recommends investors continue to add to positions and keeps a Buy rating on Broadcom.
02/28/17
OPCO
02/28/17
NO CHANGE
Target $240
OPCO
Outperform
Broadcom price target raised to $240 from $215 at Oppenheimer
Oppenheimer analyst Rick Schafer raised his price target for Broadcom to $240 from $215 ahead of what he anticipates will be a beat and raise Q4. The analyst continues to like Broadcom's dominant/diversified semis portfolio and significant free cash flow potential. He reiterates an Outperform rating on the shares.
AUPH Aurinia Pharmaceuticals
$3.71

0.15 (4.21%)

12/30/16
HCWC
12/30/16
NO CHANGE
Target $8
HCWC
Buy
Aurinia Pharmaceuticals target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Aurinia Pharmaceuticals to $8 to reflect dilution from the company's just closed equity offering. The financing removes the funding overhang, Arce tells investors in a research note. Aurinia expects its current cash is now sufficient to get it through 2017, which allows it "enough time to be thoughtful in selecting and securing additional, non-dilutive funding options, including out-licensing deals," the analyst contends. He keeps a Buy rating on the shares.
06/30/16
HCWC
06/30/16
INITIATION
Target $7
HCWC
Buy
Aurinia Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Aurinia Pharmaceuticals with a Buy rating and $7 price target.
VRML Vermillion
$2.35

0.04 (1.73%)

11/09/16
11/09/16
NO CHANGE

Vermillion's OVA1 technology receives Level B recommendation
Vermillion company Aspira Labs announced the inclusion of the OVA1 /"Multivariate Index Assay" in The American College of Obstetricians and Gynecologists Practice Bulletin Number 174, dated November 2016. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. The new guidelines now recommend that all obstetricians and gynecologists, in evaluating women with adnexal masses when the mass does not fulfill Level A criteria of a low risk transvaginal ultrasound, should use risk assessment tools such as OVA1 as listed in the bulletin. Based on this, OVA1 is the only recommended Level B tool with FDA clearance for use in assessing ovarian cancer risk in adnexal masses.
PSTG Pure Storage
$11.33

-0.07 (-0.61%)

01/06/17
OPCO
01/06/17
NO CHANGE
Target $17
OPCO
Outperform
Oppenheimer positive on Pure Storage positioning
Oppenheimer analyst Ittai Kidron is bullish on Pure Storage (PSTG) and views it as one of his top 2017 picks. The analyst is positive on the company's positioning and believes investors have not fully embraced the size of the FlashBlade opportunity and opportunity to extend its AFA technology leadership 1-2 years as it moves into NVMe. Additionally, Kidron says Pure Storage can enhance its competitive position as it leverages a strengthening relationship with Cisco (CSCO) improving its positioning against its biggest competitor, EMC (EMC). He reiterates an Outperform rating and $17 price target on Pure Storage's shares.
02/10/17
OTRG
02/10/17
UPGRADE
OTRG
Positive
Pure Storage upgraded to Positive from Mixed at OTR Global
OTR Global raised its view on Pure Storage to Positive following partner checks that indicate Q4 sales exceeded goals, solid win rates, and the Hypercovered segment that is increasingly competitive.
01/05/17
BMOC
01/05/17
UPGRADE
BMOC
Outperform
Pure Storage upgraded on growth outlook, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Pure Storage to Outperform from Market Perform. Analyst Tim Long expects the company's strong growth to continue and says that it has a "path to profitability." He thinks that the company's operating margins can turn positive by the end of 2017 and says that the decline in the stock has created a buying opportunity. Target $14.
01/24/17
JEFF
01/24/17
NO CHANGE
Target $90
JEFF
Buy
Western Digital price target raised to $90 from $80 at Jefferies
Jefferies analyst James Kisner raised his price target for Western Digital (WDC) to $90 citing an improving hard-disk drive industry and "quite healthy" NAND market. The analyst, however, believes a lot of the good news is priced in at current share levels. He keeps a Buy rating on Western Digital. Into the quarterly results for IT Hardware names, Kisner likes best shares of Seagate (STX) and Nimble Storage (NMBL). He's most cautious on the Q4 earnings for Pure Storage (PSTG) and Mellanox (MLNX).
RTRX Retrophin
$21.50

0.23 (1.08%)

11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.
PLNT Planet Fitness
$21.85

0.34 (1.58%)

08/12/16
COWN
08/12/16
NO CHANGE
Target $24
COWN
Outperform
Planet Fitness price target raised to $24 from $19 at Cowen
Cowen raised its price target on Planet Fitness to $24 from $19 following better than expected Q2 results. The firm cited the company's expansion prospects for the West Coast, compelling increasing royalty rate, and benefits from its national advertising campaign. Cowen reiterated its Outperform rating on Planet Fitness shares.
01/05/17
MACQ
01/05/17
INITIATION
Target $28
MACQ
Outperform
Planet Fitness initiated with an Outperform at Macquarie
Macquarie analyst Matthew Brooks initiated Planet Fitness with an Outperform and a $28 price target due to strong unit economics.
10/25/16
UBSW
10/25/16
NO CHANGE
Target $25
UBSW
Buy
Planet Fitness has premium valuation metrics, says UBS
UBS analyst Jonathan Komp previewed Planet Fitness ahead of its Q3 results and expects another solid quarter with ongoing brand momentum helping to support unit development, healthy same store sales, and positive overall results. Komp likes the stock at current levels and reiterated his Buy rating and $25 price target on Planet Fitness shares.
10/27/16
PIPR
10/27/16
NO CHANGE
Target $23
PIPR
Overweight
Piper continues to recommend shares of Planet Fitness
Piper Jaffray analyst Sean Naughton continues to recommend Planet Fitness shares citing the company's "strong" quarter and accelerating comps. The analyst believes mid-teens earnings growth is achievable next year and keeps an Overweight rating on the shares with a $23 price target.
SHAK Shake Shack
$36.12

0.29 (0.81%)

01/06/17
01/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. McDonald's (MCD) downgraded to Neutral from Buy at UBS with analyst Dennis Geiger saying the shares at current levels largely reflect improved fundamentals and refranchising benefits. 2. GoPro (GPRO) downgraded to Underperform from Neutral at Longbow with analyst Joe Wittine saying he predicts "another" fourth quarter camera sales miss as "a near-certainty." 3. Stryker (SYK) downgraded to Hold from Buy at Edward Jones and to Underperform from Hold at Needham. 4. Shake Shack (SHAK) downgraded to Neutral from Buy at Buckingham saying current valuation reflects "near-flawless execution." 5. Gartner (IT) downgraded to Neutral from Outperform at Macquarie with analyst Hamzah Mazari citing the CEB deal announcement given a lack of near-term catalysts and visibility surrounding revenue synergy execution. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/16
JEFF
08/11/16
NO CHANGE
Target $36
JEFF
Hold
Shake Shack shares likely range-bound in near-term, says Jefferies
Jefferies analyst Andy Barish expects Shake Shack shares to be range-bound near-term in the $30s after the company reported same-store-sales of 4.5%, not double digits. Increasing labor costs and investments make significant upside surprises less likely going forward, Barish tells investors in a post-earnings research note. He lowered his price target for the shares to $36 from $38 and keeps a Hold rating on the shares.
08/11/16
08/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Shake Shack (SHAK) upgraded to Buy from Neutral at SunTrust with analyst Jake Bartlett saying improved unit growth and its second quarter same-store sales miss creates a buying opportunity. 2. SeaWorld (SEAS) upgraded to Neutral from Underperform at Credit Suisse with analyst Benjamin Chalken citing recently lowered guidance, reset expectations, and balanced risk reward. 3. Cabot Oil & Gas (COG) upgraded to Outperform at Scotia Howard Weil with analyst Holly Stewart saying she expects infrastructure concerns will be reconciled by early 2018 with the inservice of 850 MMcf/d of contracted capacity and another 690 MMcf/d by early 2019. 4. American Eagle (AEO) upgraded to Buy from Hold at Wunderlich with analyst Eric Beder saying the company's momentum is "too strong" not to own the shares. 5. Nestle (NSRGY) upgraded to Buy from Hold at Societe Generale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/17
BUCK
01/06/17
DOWNGRADE
BUCK
Neutral
Shake Shack downgraded to Neutral from Buy at Buckingham
Buckingham downgraded Shake Shack to Neutral and maintained its $40 price target saying current valuation reflects "near-flawless execution."
NKTR Nektar
$13.01

-0.07 (-0.54%)

01/26/17
PIPR
01/26/17
NO CHANGE
PIPR
Overweight
Celgene acquisition highlights underappreciated Nektar asset, says Piper Jaffray
After Celgene (CELG) announced this morning a deal to acquire Delinia for $300M plus up to $475M in potential milestones, Piper Jaffray analyst Joshua Schimmer noted that the company's lead asset, DEL106, being developed for autoimmune disorders, is similar to Nektar's (NKTR) NKTR-358. While many investors are familiar with Nektar's immune-oncology program, NKTR-214, far fewer are familiar with NKTR-358, though both represent potential blockbuster opportunities if successful, Schimmer tells investors. He keeps an Overweight rating on Nektar, which he identifies as one of his top mid-cap picks.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
01/06/17
BTIG
01/06/17
INITIATION
Target $22
BTIG
Buy
Nektar initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started Nektar Therapeutics with a Buy rating and $22 price target. Several "intriguing" emerging therapeutics along with multiple near-term catalysts make the shares attractive, Hazlett tells investors in a research note.
01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.
SGYP Synergy Pharmaceuticals
$5.68

-0.11 (-1.90%)

02/22/17
PIPR
02/22/17
NO CHANGE
Target $205
PIPR
Neutral
Piper physician survey a 'mixed bag' for Allergan's Linzess
Piper Jaffray analyst David Amsellem says his firm's survey of 39 physicians is a "mixed bag" for Allergan's (AGN) Linzess. The feedback from doctors suggest that the prospects for double-digit annual volume growth for Linzess over the long-term "are not nearly as strong as sentiment in the broader investor community would suggest," Amsellem tells investors in a research note. A bulk of the respondents have a favorable view of Linzess but also "misgivings regarding the incidence of diarrhea," the analyst adds. Further, Amsellem does not conclude that Synergy Pharmaceuticals' (SGYP) recently approved Trulance in chronic idiopathic constipation is the "poor man's Lizness." The lower incidence of diarrhea associated with Trulance does not necessarily mean that it is a less potent agent, the analyst contends. He keeps a Neutral rating on Allergan with a $205 price target.
01/23/17
ROTH
01/23/17
NO CHANGE
Target $10.5
ROTH
Buy
Synergy Pharmaceuticals price target raised to $10.50 from $6.50 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Synergy Pharmaceuticals (SGYP) to $10.50 from $6.50 after the FDA approved Trulance for the treatment of adults with chronic idiopathic constipation, and due to Synergy Pharmaceuticals lowered risk profile and to better align with the valuation of its peer Ironwood Pharmaceuticals (IRWD). He reiterates a Buy rating on Synergy Pharmaceuticals' shares.
02/22/17
WELS
02/22/17
NO CHANGE
WELS
Underperform
Wells thinks 50-plus salespeople just left Valeant for Synergy
Wells Fargo analyst David Maris says he asked Valeant Pharmaceuticals (VRX) whether industry speculation is true regarding the company losing 50-plus gastrointestinal salespeople to Synergy Pharmaceuticals (SGYP) following the latter's recent FDA approval. Valeant indicated that a number of salespeople have left but would not confirm how many, Maris tells investors in a research note. The analyst adds that Synergy would only comment that it has been very successful in hiring a large number of experienced salespeople. The loss of 50-plus salespeople would be another setback to the Salix/gastrointestinal salesforce at a time when prescription trends on Xifaxan are already weak, Maris contends. The analyst also learned that the son of Valeant CEO Joseph Papa joined Valeant in September 2016 as a product manager for Xifaxan, the company's largest product. Maris says Valeant acknowledged that several investors have already raised the matter. Maris has an Underperform rating on the shares, which closed the trading day down 4c to $16.35.
02/24/17
WELS
02/24/17
NO CHANGE
WELS
Wells says new Valeant is not new, calls shares overvalued
The market is underestimating Valeant Pharmaceuticals' "poor" prescription trends, reliance on price, employee turnover, execution risk on product launches, patent expiries including Xifaxan and numerous lawsuits, Wells Fargo analyst David Maris tells investors in a research note titled "Deja Valeant--We See History Repeating Itself." The stock is overvalued, and despite management wanting to talk about the "new Valeant," the company's business trends and pricing-driven model remain "old Valeant," Maris contends. He cut his Q4 earnings per share estimate for the company to $1.48 from $1.48, 2017 estimate to $5.03 from $5.14 and 2018 estimate to $5.45 from $5.91. His Q4 estimate remains well above the consensus of $1.22. Maris points out that since the new management team took over in 2016, Valeant set and then lowered guidance, raised prices on more than 50 products, missed key launch targets, had manufacturing issues and saw prescription declines continue. On the positive front, the company has sold $2.3B of assets, the analyst points out. Maris, who wrote this week that Valeant likely just lost 50-plus salespeople to Synergy Pharmaceuticals (SGYP), keeps an Underperform rating on Valeant with a $10-$13 price target range. The drugmaker closed yesterday at $16.58.
BOX Box
$18.26

0.64 (3.63%)

01/10/17
WELS
01/10/17
INITIATION
WELS
Outperform
Box initiated with an Outperform at Wells Fargo
Wells Fargo analyst Philip Winslow started Box with an Outperform rating and $20-$22 price target range.
11/21/16
JMPS
11/21/16
NO CHANGE
JMPS
Box Q3 results should beat expectations, says JMP Securities
JMP Securities analyst Greg McDowell expects Box's Q3 results to beat expectations. He says that the firm's checks "suggest continued strong sales momentum, at least in some regions." The analyst adds "that the overall next generation enterprise content space remains healthy." He keeps an $18 price target and an Outperform rating on the stock.
12/01/16
ADAM
12/01/16
NO CHANGE
Target $19
ADAM
Buy
Box remains favorite small-cap, aggressive growth name at Canaccord
Canaccord analyst Richard Davis said Box remains his favorite small-cap, aggressive growth recommendation following the company's Q3 results. The analyst noted the company reported upside to just about every metric and gave solid guidance. Davis said shares appear undervalued and reiterated his Buy rating and raised his price target to $19 from $17 on Box shares.
01/09/17
OPCO
01/09/17
NO CHANGE
Target $18
OPCO
Outperform
Oppenheimer positive on Box transformation to broad enterprise content platform
Oppenheimer analyst Ittai Kidron says he is positive on Box's (BOX) transformation to a broad enterprise content platform and views it as one of his top 2017 picks. The analyst believes investors do not fully appreciate the potential of its IBM (IBM) partnership, the extent of Box's enterprise relevance, and its ability to deepen its enterprise stickiness/value as it seamlessly integrates into Microsoft (MSFT) and Google's (GOOGL; GOOG) ecosystems. Further, Kidron expects Box to continue to deliver "steady results" with potential 2018 upside. He reiterates an Outperform rating and $18 price target on Box's shares.
HDSN Hudson Technologies
$7.39

0.23 (3.21%)

07/19/16
CHLM
07/19/16
NO CHANGE
Target $9
CHLM
Buy
Hudson Technologies price target raised to $9 from $6 at Craig-Hallum
Craig-Hallum analyst Steven Dyer estimates that the "substantial award" to Hudson Technologies from the Department of Defense for the supply and distribution of refrigerants and gases will add $30M-$40M in revenue and 10c-15c of EPS on an annual basis as well favorably positioning the company to compete for additional future governmental awards. The analyst raised his price target on Hudson shares to $9 from $6 and keeps a Buy rating on the stock.
04/12/16
RILY
04/12/16
INITIATION
Target $5.75
RILY
Buy
Hudson Technologies initiated with a Buy at B. Riley
Target $5.75.
AXTI AXT, Inc.
$7.50

0.4 (5.63%)

07/28/16
NEED
07/28/16
UPGRADE
NEED
Buy
AXT, Inc. upgraded to Buy from Hold at Needham
02/13/17
DOTC
02/13/17
INITIATION
Target $8
DOTC
Buy
AXT, Inc. initiated with a Buy at Dougherty
Dougherty analyst Joe Maxa initiated AXT, Inc with a Buy and an $8 price target.
05/03/16
05/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AXT, Inc. (AXTI) upgraded to Buy at Craig-Hallum by analyst Richard Shannon following the Q1 upside driven by InP which continues to benefit from increasing demand from the optimal communications market. The analyst expects the improvement to be sustainable for a reasonable investment horizon and sees visibility into growth and GM improvement. 2. Midcoast Energy (MEP) upgraded to Neutral at Credit Suisse by analyst John Edwards, who cited the company's announcement of a strategic review. 3. Republic Services (RSG) upgraded to Overweight at Barclays with analyst Jon Windham saying he expects the waste disposal sector to experience continued per share profit growth. 4. Superior Energy (SPN) upgraded to Buy at Citi by analyst Scott Gruber, who said the company's strategy shift to potentially expand the frac business could be a "material catalyst" for the shares. 5. Intevac (IVAC) upgraded to Buy from Hold at Maxim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/16
CHLM
05/03/16
UPGRADE
CHLM
Buy
AXT, Inc. upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Richard Shannon upgraded AXT, Inc to Buy and increased its price target to $4.25 from $2.75 following the Q1 upside driven by InP which continues to benefit from increasing demand from the optical communications market. The analyst expects the improvement to be sustainable for a reasonable investment horizon and sees visibility into growth and GM improvement.
JUNO Juno Therapeutics
$25.31

1.27 (5.28%)

02/01/17
WEDB
02/01/17
INITIATION
Target $24
WEDB
Neutral
Juno Therapeutics initiated with a Neutral at Wedbush
Wedbush analyst David Nierengarten initiated Juno Therapeutics with a Neutral and a $24 price target saying competition from other CAR-T products is likely to limit upside near-term.
02/02/17
02/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kite Pharma (KITE) and Juno Therapeutics (JUNO) were initiated with a Neutral at Wedbush. 2. Penske Automotive (PAG) was initiated with a Positive at Susquehanna, while Lithia Motors (LAD) and Group 1 Automotive (GPI) were initiated with a Neutral. 3. Nevsun Resources (NSU) initiated with a Market Perform at BMO Capital. 4. Corcept Therapeutics (CORT) initiated with a Buy at Ladenburg. 5. Iteris (ITI) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/17
WELS
02/22/17
INITIATION
WELS
Outperform
Juno Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Juno Therapeutics with an Outperform rating and $34-$36 price target range. The analyst believes the company has a "best-in-class" platform in adoptive cellular therapy.
02/22/17
02/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NVIDIA (NVDA) initiated with a Buy at Rosenblatt and with a Neutral at MKM Partners. 2. Intel (INTC) initiated with a Sell at Rosenblatt and a Buy at MKM Partners. 3. Goldman Sachs (GS) and Morgan Stanley (MS) initiated with a Neutral at Compass Point. 4. Endo (ENDP) initiated with a Hold at Canaccord. 5. Juno Therapeutics (JUNO) was initiated with an Outperform at Wells Fargo, while Kite Pharma (KITE) was initiated with a Market Perform. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
KTOS Kratos Defense
$8.03

-0.22 (-2.67%)

08/29/16
KEYB
08/29/16
DOWNGRADE
KEYB
Sector Weight
Kratos Defense downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Michael Ciarmoli downgraded Kratos Defense & Security Solutions citing the recent rally in the shares.
01/19/17
RHCO
01/19/17
INITIATION
RHCO
Buy
Kratos Defense initiated with a Buy at SunTrust
SunTrust analyst Michael Ciarmoli started coverage of Kratos with a $9 price target and a Buy rating.
01/17/17
01/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kratos Defense (KTOS) initiated with a Buy at Canaccord. 2. Buckeye Partners (BPL) coverage resumed with an Equal Weight at Barclays. 3. Clovis (CLVS) and TESARO (TSRO) were initiated with an Overweight at Morgan Stanley. 4. TPI Composites (TPIC) initiated with a Buy at Roth Capital. 5. International Seaways (INSW) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/17
ADAM
01/17/17
INITIATION
Target $10
ADAM
Buy
Kratos Defense initiated with a Buy at Canaccord
Canaccord analyst Ken Herbert initiated Kratos Defense with a Buy citing belief the company is at an inflection point in its business. The analyst expects fundamentals to continue to improve as the company successfully executes on its near and long-term strategy and for the stock to continue its outperformance. He believes the current and potential portfolio in the unmanned business represents significant upside. Herbert has a $10 price target on Kratos Defense shares.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$75.82

1.97 (2.67%)

, EV

Eaton Vance

$47.16

0.58 (1.25%)

20:25
08/22/17
08/22
20:25
08/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$75.82

1.97 (2.67%)

EV

Eaton Vance

$47.16

0.58 (1.25%)

AEO

American Eagle

$11.21

0.59 (5.56%)

EXPR

Express

$5.49

0.14 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 11

    Sep

  • 12

    Sep

  • 13

    Sep

  • 14

    Sep

  • 15

    Sep

  • 21

    Nov

T

AT&T

$37.98

0.4 (1.06%)

, TWX

Time Warner

$101.80

-0.31 (-0.30%)

19:14
08/22/17
08/22
19:14
08/22/17
19:14
Hot Stocks
Mexico regulators approve AT&T-Time Warner deal »

The Instituto Federal de…

T

AT&T

$37.98

0.4 (1.06%)

TWX

Time Warner

$101.80

-0.31 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

REGI

Renewable Energy

$11.20

0.1 (0.90%)

18:50
08/22/17
08/22
18:50
08/22/17
18:50
Hot Stocks
Renewable Energy CEO: Commerce Dept. move 'victory' for job creation »

The U.S Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

INTC

Intel

$34.65

-0.27 (-0.77%)

18:37
08/22/17
08/22
18:37
08/22/17
18:37
Hot Stocks
Former Intel CFO Stacy Smith to retire at the end of January, 2018 »

In an email, Intel CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

COL

Rockwell Collins

$124.29

0.6 (0.49%)

18:36
08/22/17
08/22
18:36
08/22/17
18:36
Upgrade
Rockwell Collins rating change at Vertical Research »

Rockwell Collins upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$92.95

1.19 (1.30%)

18:24
08/22/17
08/22
18:24
08/22/17
18:24
Hot Stocks
Salesforce CEO says closed large deal with Veterans Administration »

Says federal government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

WWR

Westwater Resources

$1.32

-0.14 (-9.59%)

18:16
08/22/17
08/22
18:16
08/22/17
18:16
Hot Stocks
Westwater Resources acquires water rights for Columbus Basin Project in Nevada »

Westwater Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:03
08/22/17
08/22
18:03
08/22/17
18:03
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

ZTO

ZTO Express

$14.01

0.11 (0.79%)

18:02
08/22/17
08/22
18:02
08/22/17
18:02
Earnings
ZTO Express reports Q2 earnings per ADS 15c, consensus 14c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

URI

United Rentals

$112.44

4.04 (3.73%)

, CMI

Cummins

$153.10

1.04 (0.68%)

17:48
08/22/17
08/22
17:48
08/22/17
17:48
Hot Stocks
United Rentals acquires power equipment assets from Cummins »

United Rentals (URI) has…

URI

United Rentals

$112.44

4.04 (3.73%)

CMI

Cummins

$153.10

1.04 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

, LZB

La-Z-Boy

$31.25

0.1 (0.32%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Maxim Integrated…

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

LZB

La-Z-Boy

$31.25

0.1 (0.32%)

CREE

Cree

$23.03

0.46 (2.04%)

VNET

21Vianet

$4.58

0.03 (0.66%)

CRM

Salesforce

$92.95

1.19 (1.30%)

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

RARE

Ultragenyx

$58.85

1.94 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 23

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

  • 16

    Nov

CRM

Salesforce

$92.95

1.19 (1.30%)

17:40
08/22/17
08/22
17:40
08/22/17
17:40
Hot Stocks
Salesforce says sees FY18 margin up 125-150 bps »

Sees "slight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

MXIM

Maxim Integrated

$44.39

0.68 (1.56%)

17:34
08/22/17
08/22
17:34
08/22/17
17:34
Hot Stocks
Maxim Integrated names Sumeet Gagneja principal accounting officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 12

    Sep

CTIC

CTI BioPharma

$3.30

0.01 (0.30%)

17:33
08/22/17
08/22
17:33
08/22/17
17:33
Hot Stocks
CTI BioPharma: Chief Business Officer Matthew Plunkett resigns »

Effective August 22,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$47.84

0.51 (1.08%)

17:32
08/22/17
08/22
17:32
08/22/17
17:32
Syndicate
Breaking Syndicate news story on Unum Group »

Unum Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

FTK

Flotek

$5.50

-0.1 (-1.79%)

17:29
08/22/17
08/22
17:29
08/22/17
17:29
Hot Stocks
Flotek announces conclusion of SEC inquiry »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 16

    May

CRM

Salesforce

$92.95

1.19 (1.30%)

17:24
08/22/17
08/22
17:24
08/22/17
17:24
Hot Stocks
Salesforce says 'had best quarter ever' »

Says can reach $20B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 05

    Sep

THO

Thor Industries

$103.90

0.45 (0.43%)

17:17
08/22/17
08/22
17:17
08/22/17
17:17
Hot Stocks
Jayco announces expansion of Middlebury campus, will add 300 jobs »

Jayco, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$924.69

18.03 (1.99%)

, GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

17:14
08/22/17
08/22
17:14
08/22/17
17:14
Hot Stocks
Google introduces Chrome Enterprise »

Google introduced Chrome…

GOOG

Alphabet

$924.69

18.03 (1.99%)

GOOGL

Alphabet Class A

$940.40

19.53 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

VNET

21Vianet

$4.58

0.03 (0.66%)

17:11
08/22/17
08/22
17:11
08/22/17
17:11
Earnings
21Vianet reports Q2 EPS (12c), one estimate (11c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

17:05
08/22/17
08/22
17:05
08/22/17
17:05
Hot Stocks
root9B Technologies announces incremental funding, status of foreclosure »

root9B Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:03
08/22/17
08/22
17:03
08/22/17
17:03
Hot Stocks
Gramercy Property Trust launches new JV over Class A distribution centers »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPT

Gramercy Property Trust

$29.13

-0.03 (-0.10%)

17:01
08/22/17
08/22
17:01
08/22/17
17:01
Hot Stocks
Gramercy Property Trust to acquire $479M core logistics portfolio »

Gramercy Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIFI

Boingo Wireless

$19.57

0.32 (1.66%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Boingo Wireless director Michael Finley sells 7,500 shares »

Boingo Wireless director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

RTNB

root9B Technologies

$2.98

1.72 (136.51%)

16:55
08/22/17
08/22
16:55
08/22/17
16:55
Hot Stocks
Breaking Hot Stocks news story on root9B Technologies »

root9B Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.